The Clinical Features and Diagnosis of Adrenoleukodystrophy: A Case Series of Iranian Family
Iranian Journal of Child Neurology,
Vol. 10 No. 1 (2016),
How to Cite This Article: Karimzadeh P, Jafari N, Nejad Biglari Hb, Jabbehdari S, Alizadeh M, Alizadeh Gh, Nejad Biglari Hm, Sanii S. The Clinical Features and Diagnosis of Adrenoleukodystrophy: A Case Series of Iranian Family. Iran J Child Neurol. Winter 2016; 10(1):61-64.
Adrenoleukodystrophy disorder is one of the x-linked genetic disorders caused by the myelin sheath breakdown in the brain. In this study, we present 4 yr experience on this disorder.
Materials & Methods
The patients diagnosed as adrenoleukodystrophy in the Neurology Department of Mofid Children’s Hospital in Tehran, Iran from 2010 to 2014 were enrolled into the study. The disorder was confirmed by neuroimaging and clinical findings along with genetic and neurometabolic assessment at Reference Laboratory in Germany. We assessed age, gender, past medical history, developmental status, clinical manifestations, and neuroimaging findings of populous family with adrenoleukodystrophy.
All of the patients were one populous family with high rate of consanguineous marriages. This disorder was confirmed by genetic assessment, VLCFA and brain MRI.
c.253_254insC, p.R85Pfs112* was found in heterozygote state and the VLCFA assessment showed the typical pattern for adrenoleukodystrophy/ adrenomyeloneuropathy. This diagnosis was in agreement with the family history and the clinical history of the patient. Since there have been a number of cases in patient’s family in the past, so intensive follow-up on the family especially detection the female members of the family of childbearing age was recommended. The amount of C-26, C24/C22 and C26/C22 was elevated. All patients with the same genotype had wide ranges of clinical presentation.
Early diagnose of this disease might help us for early intervention and prenatal diagnosis for the disease in next siblings.
- Neurometabolic disorder
- Early detection
- Early intervention
How to Cite
Silveri M, De Gennaro M, Gatti C, Bizzarri C, Mosiello G, Cappa M. Voiding dysfunction in x-linked adrenoleukodystrophy: symptom score and urodynamic findings. J Urol 2004;171(6 Pt 2):2651-3.
Moser HW, Moser AB, Hollandsworth K, Brereton NH, Raymond GV. “Lorenzo’s oil” therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy. J Mol Neurosci 2007;33(1):105-13.
Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, Jambaqué I, Jakobezak C, Lemaitre A, Boureau F, Wolf C, et al. A two-year of oleic and erucic acids (“Lorenzo’s oil”) as treatment for adrenomyeloneuropathy. N Engl J Med 1993;329(11):745-52.
Semmler A, Köhler W, Jung HH, Weller M, Linnebank M. Therapy of X-linked adrenoleukodystrophy. Expert Rev Neurother 2008;8(9):1367-79.
Watkins PA, Gould SJ, Smith MA, Braiterman LT, Wei HM, Kok F, Moser AB, Moser HW, Smith KD.Altered expression of ALDP in X-linked adrenoleukodystrophy. Am J Hum Genet 1995;57(2):292-301.
Moser HW. Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome. J Inherit Metab Dis 1995;18(4):435-47.
Brett EM, Auchus RJ. Genetic Forms of Adrenal Insufficiency. Endocr Pract 2015:1-17.
Eiben RM, DiChiro G. Computer assisted tomography in adrenoleukodystrophy. J Comput Assist Tom Ogr Ml 1:308-317.
Volkow ND, Patchell L, Kulkarni MV, Reed K, Simmons M.Adrenoleukodystrophy: imaging with CT, MRI, and PET. J Nucl Med 1987;28(4):524-7.
- Abstract Viewed: 317 times
- PDF Downloaded: 231 times